A national survey reveals correctional leaders see LAI buprenorphine as key to reducing medication diversion for opioid treatment.
Quiver AI Summary
Indivior PLC announced results from a national survey published in the Journal of Correctional Health Care, revealing that correctional leaders see staffing and coordination issues as major obstacles to reducing medication diversion for opioid use disorder (MOUD). The survey, which included responses from 180 correctional professionals, indicated that a significant majority believe long-acting injectable (LAI) buprenorphine could help mitigate diversion and enhance treatment in jails and prisons. Despite acknowledging the potential of LAI buprenorphine, respondents also pointed out the challenges of cost and limited access, along with structural barriers like inadequate staffing and poor coordination between healthcare and custody services. The findings emphasize the importance of simplifying treatment delivery in the criminal justice system and suggest that policies aimed at improving staffing and care coordination are essential for effective MOUD implementation.
Potential Positives
- The survey results showcase strong support among correctional professionals for long-acting injectable (LAI) buprenorphine, with 88% of jail staff and 87% of prison staff recognizing its potential to reduce medication diversion, enhancing Indivior's credibility and relevance in the field.
- The press release highlights Indivior's commitment to addressing complex issues within correctional health care, positioning the company as a leader in providing innovative solutions for opioid use disorder treatment.
- Indivior's partnership with the National Commission on Correctional Health Care lends additional credibility to the survey findings, reinforcing the company's dedication to evidence-based practices and collaboration in the sector.
Potential Negatives
- Despite support for long-acting injectable buprenorphine, the survey indicates significant barriers such as inadequate staffing and limited care coordination within correctional facilities, which may hinder the implementation of effective treatment programs.
- Respondents highlighted cost and limited access to resources as significant obstacles to the delivery of medication for opioid use disorder, potentially reflecting negatively on Indivior's ability to fully address the needs of these facilities.
- The sample of respondents may not be generalizable across the United States, which raises concerns about the broader applicability of the survey findings and the effectiveness of proposed strategies in diverse settings.
FAQ
What were the key findings of the Indivior survey on MOUD diversion?
The survey revealed that staffing and coordination gaps hinder efforts to reduce medication diversion in correctional facilities.
How can LAI buprenorphine help in correctional settings?
LAI buprenorphine can ease logistical burdens, improve treatment adherence, and expand access to medication for opioid use disorder.
What barriers did correctional leaders identify regarding MOUD programs?
Leaders noted issues like inadequate staffing, limited coordination between services, and challenges in medication administration and monitoring.
What is the significance of the survey conducted by Indivior?
The survey underscores the importance of simplifying treatment delivery to enhance the effectiveness of MOUD programs in corrections.
What future steps are recommended based on the survey insights?
Policies and funding strategies should focus on improving staffing, care coordination, and sustainable MOUD delivery during incarceration and reentry.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INDV Insider Trading Activity
$INDV insiders have traded $INDV stock on the open market 8 times in the past 6 months. Of those trades, 8 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $INDV stock by insiders over the last 6 months:
- DAVID E. WHEADON purchased 1,771 shares for an estimated $62,680
- STUART A KINGSLEY purchased 940 shares for an estimated $29,953
- BARBARA RYAN has made 3 purchases buying 814 shares for an estimated $28,687 and 0 sales.
- DANIEL A NINIVAGGI purchased 775 shares for an estimated $27,429
- MARK STEJBACH purchased 775 shares for an estimated $27,429
- KEITH HUMPHREYS purchased 775 shares for an estimated $27,429
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$INDV Hedge Fund Activity
We have seen 156 institutional investors add shares of $INDV stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OAKTREE CAPITAL MANAGEMENT LP removed 250,676,754 shares (-97.2%) from their portfolio in Q4 2025, for an estimated $8,994,281,933
- BLACKROCK, INC. added 9,501,401 shares (+108.8%) to their portfolio in Q4 2025, for an estimated $340,910,267
- MADISON AVENUE PARTNERS, LP removed 6,463,585 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $231,913,429
- TWO SEAS CAPITAL LP removed 5,394,954 shares (-51.4%) from their portfolio in Q4 2025, for an estimated $193,570,949
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 3,593,748 shares (-51.4%) from their portfolio in Q4 2025, for an estimated $128,943,678
- FULLER & THALER ASSET MANAGEMENT, INC. added 3,201,639 shares (+101.0%) to their portfolio in Q4 2025, for an estimated $114,874,807
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND added 2,304,545 shares (+inf%) to their portfolio in Q4 2025, for an estimated $82,687,074
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$INDV Analyst Ratings
Wall Street analysts have issued reports on $INDV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/12/2026
- Piper Sandler issued a "Overweight" rating on 10/31/2025
To track analyst ratings and price targets for $INDV, check out Quiver Quantitative's $INDV forecast page.
$INDV Price Targets
Multiple analysts have issued price targets for $INDV recently. We have seen 2 analysts offer price targets for $INDV in the last 6 months, with a median target of $44.5.
Here are some recent targets:
- Brandon Folkes from HC Wainwright & Co. set a target price of $48.0 on 01/12/2026
- David Amsellem from Piper Sandler set a target price of $41.0 on 10/31/2025
Full Release
RICHMOND, Va., April 16, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) today announced results from a national survey published in the Journal of Correctional Health Care showing that correctional leaders identify staffing and coordination gaps as key barriers to reducing diversion of medications for opioid use disorder (MOUD) and recognized long-acting injectable (LAI) buprenorphine as a strategy to help mitigate diversion and improve treatment in jail and prison settings.
The cross-sectional survey included responses from 180 correctional professionals across U.S. jail and prison facilities. Among respondents, a strong majority — 88% of those working in jails and 87% in prisons — reported that LAI buprenorphine could help reduce MOUD diversion within their facilities.
“As national policy attention turns toward strengthening long‑term recovery, these key insights highlight how treatment models that simplify delivery can strengthen MOUD implementation in criminal justice settings,” said Vanessa Procter, Executive Vice President, Corporate Affairs at Indivior. “LAI buprenorphine can reduce logistical burden, support adherence, and help criminal justice settings expand access while addressing diversion risk.”
Beyond diversion concerns, respondents identified structural barriers to effective implementation of MOUD programs, including inadequate medical and custody staffing, limited coordination between custody and health services, and operational challenges related to medication administration and monitoring.
“From a systems perspective, treatment approaches that reduce complexity while maintaining evidence-based care have the potential to support both patient access and institutional operations,” said Christian Heidbreder, PhD, Chief Scientific Officer at Indivior. “These key insights reinforce long-acting injectable buprenorphine as a viable implementation strategy supported by the care team.”
Respondents recognized that LAI buprenorphine may help reduce diversion, but they also noted that cost and limited access remain significant barriers. These key insights highlight the need for policies and funding strategies that strengthen staffing capacity, enhance care coordination, and ensure sustainable MOUD delivery during incarceration and throughout reentry into the community.
This survey was funded by Indivior and conducted in partnership with the National Commission on Correctional Health Care (NCCHC). Respondents are from a sample of individuals registered with the NCCHC and may not be generalizable across the United States. The full survey results and limitations are available here .
About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior .
For Further Information
Investors:
Jason Thompson Indivior Pharmaceuticals
Tel: 804-402-7123
E-mail:
[email protected]
Media:
Cassie France-Kelly Indivior Pharmaceuticals
Tel: 804-594-0836
E-mail:
[email protected]
